���沙莫瑞林历史与监管定位 — What the Evidence Shows

By Editorial Desk · published 2025-07-02 · last reviewed 2025-08-04 · Guide

Everything below concerns GHRH receptor. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.

Last reviewed on 2025-08-04. Where a claim depends on a specific study, the study is described rather than over-claimed.

特沙莫瑞林历史与监管定位

监管记录显示，特沙莫瑞林于 2010 年在美国首次获得批准，用于人类免疫缺陷病毒感染相关的脂肪营养不良患者。批准依据来自降低内脏脂肪的临床试验，而非体重或瘦体重的普遍改善。后续出现了不同制剂版本，但其核心适应症保持一致。关于长期心血管结局和死亡率影响，现有证据仍不充分。

在临床研究之外，特沙莫瑞林常被讨论为生长激素分泌促进剂，但这一说法需要限定。它并不等同于生长激素本身，也不属于普通减重药物。部分研究关注其减少腹部脂肪和改善脂质谱的潜力，另一些研究则关注胰岛素抵抗和 IGF-1 升高等信号。这些效应的临床意义仍在评估中，尚未形成统一结论。

特沙莫瑞林是一种合成肽，其序列与人生长激素释放激素的 44 个氨基酸形式相关。它在 N 端带有反式-3-己烯酰基修饰，这一改动可减缓二肽基肽酶 IV 的降解。该化合物属于生长激素释放激素受体激动剂，可刺激垂体释放生长激素。研究文献通常将其归入合成肽类药物，而非小分子化合物。

Mechanism and Pharmacodynamics

Pharmacodynamic studies show that tesamorelin reduces visceral adipose tissue more than subcutaneous adipose tissue in the studied population. This selectivity may relate to differences in blood flow and hormone sensitivity between fat depots. Effects on glucose metabolism and insulin sensitivity have been investigated, with some trials reporting modest changes and others showing stability. The precise relationship between growth hormone exposure, IGF-1 levels, and visceral fat loss remains an active area of analysis.

Tesamorelin binds to growth hormone-releasing hormone receptors on somatotroph cells in the anterior pituitary. Receptor activation increases intracellular cyclic AMP and promotes synthesis and secretion of growth hormone. Because the peptide mimics endogenous GHRH, it amplifies the normal pulsatile release of growth hormone rather than providing exogenous growth hormone directly. This upstream action distinguishes tesamorelin from recombinant growth hormone preparations and from growth hormone secretagogues that act at different receptors.

Stimulated growth hormone release leads to hepatic production of insulin-like growth factor 1, a key mediator of many growth hormone effects. In clinical studies, tesamorelin increased IGF-1 levels in a dose-dependent manner, although the response varies among individuals. The drug's effect on visceral fat is thought to involve growth hormone-mediated lipolysis and altered adipocyte metabolism. Muscle mass and lean body mass have also been assessed as secondary outcomes, but changes are generally smaller and less consistent than fat reductions.

Tesamorelin at a glance

Background and Clinical Development

Clinical interest in tesamorelin arose from the need to address visceral adiposity in people living with HIV. Antiretroviral therapy improved survival but was associated in some patients with central fat accumulation, altered lipid profiles, and metabolic complications. This condition, often called HIV-associated lipodystrophy, involves excess visceral adipose tissue that is difficult to manage through diet and exercise alone. Investigators evaluated tesamorelin because GHRH analogs can stimulate growth hormone secretion and influence fat distribution without direct liposuction or invasive procedures.

A Phase 3 program led to regulatory approval in the United States in 2010 for reduction of excess visceral abdominal fat in adults with HIV and lipodystrophy. Subsequent studies examined effects on liver fat, muscle area, and metabolic markers, with mixed findings for some endpoints. Long-term cardiovascular outcomes and effects on mortality remain uncertain because most trials were relatively short and focused on imaging-based fat measurements. Use in populations without HIV has been studied experimentally but is not part of the approved indication.

Related pages on this site

• Lightweight overview
• Connected casebook
• Standard notes
• Sustainable primer
• Connected notes
• Comprehensive collection
• Lightweight collection
• Regional casebook

Mechanism And Pharmacodynamic Markers

Whether the drug improves hard clinical outcomes is not settled. No completed trial has shown a reduction in heart attacks or strokes among treated patients, although a dedicated cardiovascular outcomes study has been discussed in the literature. Investigators have also examined hepatic fat in people with HIV and fatty liver disease, cognitive measures in small cohorts, and changes in bone density. Regulatory labeling emphasizes monitoring of insulin-like growth factor 1 because supraphysiologic levels raise questions about tissue growth, and the clinical significance of that signal remains an open question rather than a demonstrated harm.

Binding of tesamorelin to the growth hormone-releasing hormone receptor on anterior pituitary somatotrophs activates a Gs protein pathway, raises cyclic AMP, and triggers release of stored growth hormone into the bloodstream. Because the analogue resists dipeptidyl peptidase-4, its plasma residence time exceeds that of native GHRH, producing a larger and more sustained secretory signal. The released growth hormone then acts on the liver and peripheral tissues to raise insulin-like growth factor 1, which feeds back on the hypothalamus and pituitary. This axis explains both the intended effects on fat distribution and the biological markers used to track them.

Background And Regulatory Development

Tesamorelin occupies a narrow position among agents that act on the growth hormone axis. Unlike growth hormone itself, which is given as replacement, it stimulates the pituitary to release the hormone in pulses, so the downstream increase in insulin-like growth factor 1 depends on intact somatotroph function. Other peptides in the same family include shorter GHRH fragments and synthetic secretagogues with different stability profiles. Several points remain unresolved, including whether the reduction in visceral fat translates into fewer cardiovascular events, what happens to metabolic markers after long-term use, and how the drug compares with lifestyle or surgical approaches.

Tesamorelin is a synthetic peptide that belongs to the growth hormone-releasing hormone family and contains the same forty-four amino acid sequence as endogenous GHRH, extended at the amino terminus by a trans-3-hexenoyl group. That small fatty acid modification protects the peptide from rapid cleavage by dipeptidyl peptidase-4, the enzyme that shortens the half-life of native GHRH to only a few minutes. Chemically the compound is produced by solid-phase peptide synthesis, purified by chromatography, and supplied as a sterile lyophilized powder for reconstitution.

Background from the literature

Vasoactive intestinal peptide (VIP; PHM27) Pituitary adenylate cyclase activating peptide (PACAP) Peptide PHI 27 (peptide histidine isoleucine 27) Growth hormone releasing hormone (GHRH) 1-24 Glucagon Secretin

=== Health and death === On September 16, 1999, Barker was in Washington, D.C., to testify before Congress regarding proposed legislation that would ban captive elephants from traveling shows, such as circuses. While preparing for the presentation, Barker experienced what he called clumsiness in his right hand. Barker was admitted to George Washington University Hospital and diagnosed with a partially blocked left carotid artery. He underwent carotid endarterectomy to remove the blockage. The procedure went well enough that Barker was able to return to work within the month. Three years later, Barker had two additional health crises after taping the 30th-season finale of The Price is Right. While lying in the sun on May 30, 2002, he experienced a stroke and was hospitalized; six weeks later, on July 11, Barker underwent prostate surgery. Both hospitalizations occurred at George Washington University Hospital in Washington, D.C. and both surgeries were successful. Barker had several mild bouts with skin cancer, a result of his frequent tanning. Barker consulted a dermatologist regularly to make sure any cancers were caught and removed before they spread; they did not pose a threat to his life. During a televised interview, Barker told viewers, "I urge anyone who has spent some time in the sun, whether you're doing it now or not, go to a dermatologist once a year." On October 20, 2015, two police officers passing Barker's Los Angeles-area home saw him trip and fall on a sidewalk.

== Medical uses == Lisinopril is typically used for the treatment of high blood pressure, congestive heart failure, and diabetic nephropathy and after acute myocardial infarction (heart attack). Lisinopril is part of the ACE inhibitors drug class. Lisinopril is indicated for the treatment of hypertension, adjunctive therapy for heart failure, and acute myocardial infarction.

==== Phase II and III ==== Phase II and IIIa trials of the vaccine were carried out at the same time in Bắc Ninh, Hanoi and Long An with a total of 1,000 volunteers. The trial work in the northern localities is carried out by Hanoi Medical University and Pasteur Institute in Ho Chi Minh City in the south. In Bắc Ninh, from 20 to 23 September, the research team started recruiting volunteers and selected 338 people aged 18-65, who received the first dose from 27 to 29 September. In Long An and Hanoi, the Ministry of Health also implemented the first dose for volunteers. The phase IIIa trial is expected to end on 24 November, and the research team will report the results of the trial to the Ministry of Health on 30 December.

=== Sickle Cell === Sickle-cell disease changes the shape of red blood cells from round to sickle shaped. In the most common variant of sickle-cell disease, the 20th nucleotide of the gene for the beta chain of hemoglobin is altered from the codon GAG to GTG. Thus, the 6th amino acid, glutamic acid, is substituted by valine—notated as an "E6V" or a "Glu6Val" mutation—which causes the protein to be sufficiently altered with a sickle-cell phenotype. The affected cells cause issues in the bloodstream as they can become sticky due to their improper ion transport leading to them being susceptible to water loss. This can cause a buildup of blood cells that obstructs blood flow to any organ in the body.

Sources: en.wikipedia.org

Further detail

=== Photosynthetic prokaryotic lineages === Early photosynthetic systems, such as those in green and purple sulfur and green and purple nonsulfur bacteria, are thought to have been anoxygenic, and used various other molecules than water as electron donors. Green and purple sulfur bacteria are thought to have used hydrogen and sulfur as electron donors. Green nonsulfur bacteria used various amino and other organic acids as electron donors. Purple nonsulfur bacteria used a variety of nonspecific organic molecules. The use of these molecules is consistent with the geological evidence that Earth's early atmosphere was highly reducing at that time. With a possible exception of Heimdallarchaeota, photosynthesis is not found in archaea. Haloarchaea are photoheterotrophic; they can absorb energy from the sun, but do not harvest carbon from the atmosphere and are therefore not photosynthetic. Instead of chlorophyll they use rhodopsins, which convert light-energy to ion gradients but cannot mediate electron transfer reactions. In bacteria eight photosynthetic lineages are currently known:

== Measurement and values == Measurement is done from a sample of venous blood using immunological measuring mechanisms like ELISA, RIA, etc. Often these are done by automated machines to minimize human error.

Sierra View Medical Center is a 167-bed, full-service acute care hospital located in Porterville, California. Founded in 1958, the hospital serves the Southern Sequoia region of California's Central Valley. Services include cancer care, an intensive-care unit and respiratory care. The hospital is a part of the Sierra View Local Healthcare District. It offers a wide range of health care services featuring state of the art technologies including Magnetic Resonance Imaging (MRI) and Computed Tomography (CT). The hospital is also home to the Roger S. Good Cancer Treatment Center, which hosts clinical trials of the University of California Los Angeles in oncology. In July 2007, the hospital opened a 32-station outpatient Dialysis Center. The hospital's Wound Healing Center is managed by Healogics. Sierra View Medical Center was awarded the Joint Commission's Gold Seal of Approval for Primary Stroke Centers in 2021, demonstrating compliance with high standards in quality improvement for patient outcomes. The hospital also received the organization's Pioneers in Quality award in 2017. Sierra View Medical Center received the Get With The Guidelines - Stroke GOLD PLUS with Target: Type 2 Diabetes Honor Roll from the American Heart Association. It is also the only hospital in Tulare County to be designated "Baby Friendly" following a World Health Organization and UNICEF-supported initiative aimed at promoting breastfeeding. The Wound Healing Center was awarded the Healogics Robert A. Warriner III Center of Excellence in 2018.

=== Antimicrobial packaging === Antimicrobial packaging is designed to inhibit pathogenic or spoilage microorganisms on a product surface or within the package environment. Antimicrobial compounds may be incorporated into films and coatings, immobilised on a package surface, released into the package headspace, or contained in pads, labels, and separate emitters. Studied agents include organic acids, plant-derived compounds, enzymes, bacteriocins, metal ions, nanoparticles, and synthetic antimicrobial substances. The performance of antimicrobial packaging depends on the target microorganism, active-agent concentration, release rate, temperature, food composition, storage period, and contact between the package and the product. Absorbent pads used with meat, poultry, seafood, and fresh produce can combine liquid absorption with antimicrobial substances or freshness indicators.

Sources: en.wikipedia.org

Background from the literature

Thyroglobulin (Tg) acts as a substrate for the synthesis of the thyroid hormones thyroxine (T4) and triiodothyronine (T3), as well as the storage of the inactive forms of thyroid hormone and iodine within the follicular lumen of a thyroid follicle. Newly synthesized thyroid hormones (T3 and T4) exist as prohormonal modified tyrosine residues of thyroglobulin, which comprise the colloid within the follicle. When stimulated by thyroid stimulating hormone (TSH), the colloid of the follicular lumen is endocytosed into the surrounding thyroid follicular epithelial cells. When endosomes fuse with lysosomes in these cells, Tg is subsequently cleaved by proteases to release thyroglobulin from its T3 and T4 attachments. Because of the hydrophobic nature of T3 and T4, they are able to then diffuse across the lysosomal membrane and into the cytoplasm. The active forms of thyroid hormone (T3 and T4), are then released into circulation where they are either unbound or attached to plasma proteins. Iodine is recycled back into the follicular lumen where it can continue to serve as a substrate for thyroid hormone synthesis, while the non-modified residues of Tg reenter cellular metabolic pathways.

=== Parkinson's disease === Barran has been working with Joy Milne to search for odorous biomarkers of Parkinson's disease. By smelling skin swabs, Milne says she can differentiate between people with and without Parkinson's disease. She says she identified changes in her husband's scent before he was formally diagnosed with Parkinson's disease, which he died of in 2015. Barran uses mass spectrometry to investigate the biomarkers of Parkinson's disease. The story was made into a BBC documentary The Woman Who Can Smell Parkinson's. Barran received ethical approval for her work of the skin metabolites of Parkinson's in 2015, allowing them to work with Parkinson's UK to conduct a larger study. In 2018 Milne travelled to the Tanzanian training centre APOPO to check whether she could smell Tuberculosis. Barran's work on Parkinson's is sponsored by The Michael J. Fox Foundation. In 2022, Barran and others published a study of a method to detect Parkinson's disease by analysing sebum using mass spectrometry.

== Environmental Impact == Parcel to pallet sized insulated shipping containers have historically been single-use products due to the low-cost material composition of EPS and water-based gel packs. The insulation material typically finds its way into landfill streams as it is not readily recyclable in the United States. The development of reusable high-performance shipping containers have been shown to reduce packing waste by 95% while also contributing significant savings to other environmental pollutants.

=== Fourth wave (2016–present) === The fourth wave, which began in 2016, is characterized by polysubstance use and increased use of stimulants like methamphetamines and cocaine. Additionally, this wave is characterized by the emergence of novel adulterants, such as xylazine and more recently medetomidine in the fentanyl supply. The availability and use of illicit fentanyl continue to be the leading cause of fatalities, but the recent rise of polysubstance use, defined as the practice of using multiple drugs at once or in succession, and stimulants, is linked to the increased fatality rate with the ongoing opioid epidemic. Between 2012 and 2018, there was a threefold increase in mortality related to cocaine use, and a fivefold increase in mortality related to psychostimulants like methamphetamine. This increase has primarily been observed in male populations from non-Hispanic American Indian, non-Hispanic Black, and non-Hispanic White populations. Researchers attribute the increase in illicit drug use to the CDC's recommendations to reduce opioid use through measures like tapering opioid prescribing. In 2023, opioid deaths began a sustained decline after peaking at 73,000 that year. Deaths declined by over 1/3 in 2024. The decline is attributed to the reduced availability of fentanyl precursors from China, as the quality of fentanyl decline along supply chains affecting production in both Mexico and China.

==== Relapses ==== Relapses are usually unpredictable, occurring without warning. Exacerbations rarely occur more frequently than twice per year. Some relapses, however, are preceded by common triggers and they occur more frequently during spring and summer. Similarly, viral infections such as the common cold, influenza, or gastroenteritis increase their risk.Stress may also raise attack risk modestly, with the strongest evidence for severe stress like war or in PTSD. Many events do not affect rates of relapse requiring hospitalization including vaccination, breast feeding, physical trauma, and Uhthoff's phenomenon.

Sources: en.wikipedia.org

Frequently asked questions